227 related articles for article (PubMed ID: 32370777)
1. Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR.
Hoffmann S; Crispin A; Lindoerfer D; Sroczynski G; Siebert U; Mansmann U; Consortium F
BMC Gastroenterol; 2020 May; 20(1):131. PubMed ID: 32370777
[TBL] [Abstract][Full Text] [Related]
2. Colorectal Cancer Screening for Persons With a Positive Family History—Evaluation of the FARKOR Program for the Secondary Prevention of Colorectal Cancer in Persons Aged 25 to 50.
Crispin A; Rehms R; Hoffmann S; Lindoerfer D; Hallsson LR; Jahn B; Mühlberger N; Sroczynski G; Siebert U; Mansmann U
Dtsch Arztebl Int; 2023 Nov; 120(46):786-792. PubMed ID: 37855423
[TBL] [Abstract][Full Text] [Related]
3. Positive family history of colorectal cancer in a general practice setting [FRIDA.Frankfurt]: study protocol of a of a cross-sectional study.
Siebenhofer A; Plath J; Taubenroth M; Singer S; Hechtner M; Dahlhaus A; Rauck S; Schulz-Rothe S; Koné I; Gerlach FM
BMC Cancer; 2015 Aug; 15():605. PubMed ID: 26314581
[TBL] [Abstract][Full Text] [Related]
4. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
6. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
[TBL] [Abstract][Full Text] [Related]
7. Long-term benefits and harms of early colorectal cancer screening in German individuals with familial cancer risk.
Sroczynski G; Hallsson LR; Mühlberger N; Jahn B; Rehms R; Hoffmann S; Crispin A; Lindoerfer D; Mansmann U; Siebert U
Int J Cancer; 2024 Feb; 154(3):516-529. PubMed ID: 37795630
[TBL] [Abstract][Full Text] [Related]
8. Study protocol of the RaPS study: novel risk adapted prevention strategies for people with a family history of colorectal cancer.
Tikk K; Weigl K; Hoffmeister M; Igel S; Schwab M; Hampe J; Klug SJ; Mansmann U; Kolligs F; Brenner H
BMC Cancer; 2018 Jul; 18(1):720. PubMed ID: 29976178
[TBL] [Abstract][Full Text] [Related]
9. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
[TBL] [Abstract][Full Text] [Related]
11. [Results and cost-effectiveness of colorectal cancer screening program among urban residents in Zhejiang province, 2013-2018].
Wang L; Li HZ; Zhu C; Wang YQ; Zhou HJ; Sun XH; Zhang MZ; Jin L; Du LB
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Dec; 41(12):2080-2086. PubMed ID: 33378820
[No Abstract] [Full Text] [Related]
12. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE
Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021
[TBL] [Abstract][Full Text] [Related]
14. Budget Impact Analysis of Against Colorectal Cancer In Our Neighborhoods (ACCION): A Successful Community-Based Colorectal Cancer Screening Program for a Medically Underserved Minority Population.
Kim B; Lairson DR; Chung TH; Kim J; Shokar NK
Value Health; 2017 Jun; 20(6):809-818. PubMed ID: 28577699
[TBL] [Abstract][Full Text] [Related]
15. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
Guo F; Chen C; Schöttker B; Holleczek B; Hoffmeister M; Brenner H
Int J Cancer; 2020 May; 146(9):2423-2432. PubMed ID: 31291471
[TBL] [Abstract][Full Text] [Related]
16. [Rates on the acceptance of colonoscopy, fecal immunochemical test and a novel risk-adapted screening approach in the screening programs of colorectal cancer as well as related associated factors].
Chen HD; Lu M; Liu CC; Zhang YH; Zou SM; Shi JF; Ren JS; Li N; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Oct; 41(10):1655-1661. PubMed ID: 33297622
[No Abstract] [Full Text] [Related]
17. Colon Cancer Screening - Is It Time Yet?
Bhurgri H; Samiullah S
J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
[TBL] [Abstract][Full Text] [Related]
18. Comparing the effect of a decision aid plus patient navigation with usual care on colorectal cancer screening completion in vulnerable populations: study protocol for a randomized controlled trial.
Brenner AT; Getrich CM; Pignone M; Rhyne RL; Hoffman RM; McWilliams A; de Hernandez BU; Weaver MA; Tapp H; Harbi K; Reuland D
Trials; 2014 Jul; 15():275. PubMed ID: 25004983
[TBL] [Abstract][Full Text] [Related]
19. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
[TBL] [Abstract][Full Text] [Related]
20. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
